^
    Back
    Association details:
    Biomarker:Chr del(11q)
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Rituxan (rituximab) (CD20 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Outcomes for CLL with del(11q) are better with chemoimmunotherapy containing an alkylating agent. Therefore, FR is not recommended for CLL with del(11q).
    Secondary therapy:
    fludarabine oral
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy

    Excerpt:
    ...- POOR PROGNOSTIC FEATURES (before induction ICT) defined by at least one of the following markers: stage C Binet, unmutated IgVH genes, 17p deletion, 11q deletion, Zap-70 positivity, high CD38, mutated IgVH genes if VH3-21 usage...
    Trial ID:
    HYDRIC
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

    Excerpt:
    ...- Poor-risk small lymphocytic lymphoma or chronic lymphocytic leukemia, defined by a 17p deletion, 11q deletion, or histologic conversion (if histologic conversion, PR or CR is required)...
    Trial ID:
    NCT00946023
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia

    Excerpt:
    ...- 11q deletion by FISH...
    Trial ID:
    NCT00343447
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    High-dose Methylprednisolone and Rituximab in High Risk B-CLL

    Excerpt:
    ...- 11q del confirmed by FISH or...
    Trial ID:
    LT-CLL-001
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

    Excerpt:
    ...MRD (minimal residual disease) progression free survival`conversion rate to MRD negative`median MRD levels`conversation rate to CR`effect of MRD levels on clinical PFS and OS`event free survival`time to next treatment`overall survival`Safety of Rituximab maintenance treatment in patients with CLL`benefit according to cytogenetic risk group (trisomy 12, del 11q, del 17p and del 13q), IgVH mutation status, ZAP 70 and CD38 expression...
    Trial ID:
    NCT01118234
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia

    Excerpt:
    ...- MRD-progression free survival- PFS and MRD PFS in relation to gender - conversion rate to MRD negative- median MRD levels- conversion rate to CR- effect of MRD levels on clinical PFS and OS- Event free survival- Time to next treatment- overall survival- safety- benefit according to cytogenetic risk group (trisomy 12, del 11q, del 17p and del 13q ), IgVH mutation status, ZAP 70 and CD38 expression`- MRD-progression free survival - PFS and MRD PFS in relation to gender - conversion rate to MRD negative - median MRD levels - conversion rate to CR - effect of MRD levels on clinical PFS and OS - Event free survival - Time to next treatment - overall survival - safety - benefit according to cytogenetic risk group (trisomy 12, del 11q, del 17p and del 13q ), IgVH mutation status, ZAP 70 and CD38 expression`MRD-progression free survival conversion rate to MRD negative median MRD levels conversion rate to CR effect of MRD levels on clinical PFS and OS event free survival time to next treatment OS safety benefit according to cytogenetic risk groups...
    Trial ID:
    2009-013651-29